ModifiedUnitedHealthcarePolicy N/A

Provider Administered Drugs - Site of Care (Louisiana only)

Defines medical benefit coverage and site-of-care criteria for hospital outpatient infusion versus alternative infusion settings for specified provider-administered specialty medications in Louisiana.

Policy Summary

PayerUnitedHealthcare

PolicyProvider Administered Drugs - Site of Care (Louisiana only)

Policy CodePolicy N/A

Change TypeMaterial revisions to clinical criteria and HCPCS coding

Effective DateMay 1, 2025

Next Review DateN/A

Key ActionSubmit medical records documenting that outpatient hospital facility-based administration is medically necessary and that the individual meets at least one specified clinical criterion.

SourceLink

POLICY UPDATE CHANGES

Replaced language requiring submission of medical records only when outpatient hospital facility-based infusion is medically necessary with language requiring submission of medical records documenting that outpatient hospital facility-based administration is medically necessary.

Added criterion that the patient is medically unstable and at risk of requiring services/equipment available only in an outpatient hospital setting (examples listed), including history of cardiopulmonary conditions, inability to tolerate fluid volume load, or severe patent vascular access issues.

Changed wording to require prior serious adverse events while receiving the requested therapy (excluding first or second infusion) that were unresponsive to standard interventions before considering alternative sites higher risk.

Clarified initial infusion/re-initiation language to exclude drugs dosed at intervals of 6 months or greater when defining re-initiation requirements.

Revised list of medications requiring healthcare provider administration and added guselkumab (Tremfya); added and revised HCPCS codes including J1552, J1628, Q5133, and Q5135.

~50+listed specialty medications and biologics referenced for site-of-care policy

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Outpatient Hospital Facility-Based Administration

Continuation/ongoing therapy

Ongoing therapy authorization limits

Duration limit: Ongoing outpatient hospital facility-based infusion authorization will be no more than 6 months to allow reassessment for alternative Sites of Care<= 6 months

If more than one applicable approval time period exists, the greatest is allowed

Criteria for outpatient hospital facility-based administration

Outpatient hospital facility-based administration is allowed when AT LEAST ONE of the following criteria is documented and supported by medical records:

Medical instability

Examples of medical instability: History of cardiopulmonary conditions that increase risk of severe adverse reactions during or immediately following infusion; inability to tolerate fluid volume load (intravenous infusions only) despite using the minimum amount of fluid required for infusion (e.g., unstable renal function); severe patent vascular access issues (intravenous infusions only) requiring specialized equipment only available in an outpatient hospital setting (e.g., ultrasound guidance) and member is not a viable candidate for long-term vascular access devices such as PICC line or port-a-cath.

Prior severe adverse events: Previous episode(s) of severe or potentially life-threatening adverse events (e.g., anaphylaxis, seizure, thromboembolism, myocardial infarction, renal failure), not including the first or second infusion, that have occurred while receiving the requested therapy and were unresponsive to acetaminophen, steroids, diphenhydramine, fluids, infusion rate reductions, or other pre-medications, thereby increasing risk when administering at alternative sites of care.n=1

Documentation required (infusion records, medical records).

Site/Environment or caregiver concerns: Treatment at an alternative Site of Care presents a health risk due to a clinically significant physical or cognitive impairment, or the homecare/home infusion provider has deemed the individual or home environment not suitable for home infusion therapy.n=1

Documentation from homecare/provider is required.

Initial/re-initiation therapy: Initial infusion or re-initiation of previous therapy after more than 6 months (excludes drugs dosed at an interval of 6 months or greater) for a short duration of time (e.g., 4 weeks) may warrant outpatient hospital facility-based administration.n=1

Applies to initial or short re-initiation periods only.

The list of procedure and HCPCS/CPT codes provided in this policy is for reference only. Inclusion of a code does not imply the service described is covered or non‑covered, nor does it guarantee reimbursement. Benefit coverage is subject to applicable federal, state, and contractual requirements and other policies that may apply.

This policy revision removed the prior blanket language that automatically excluded alternative sites of care based solely on a member's complex medical status or need for enhanced monitoring. That broad criterion has been replaced with more specific, measurable medical‑necessity examples that must be documented to justify hospital outpatient facility‑based administration.

When an individual does not meet any of the specified clinical criteria for hospital outpatient facility infusion, consider alternative Sites of Care such as non‑hospital outpatient infusion, physician office, ambulatory infusion suites, or home infusion. Clinical appropriateness for these alternative sites should be based on the documented risk profile and shared decision‑making with the treating clinician.

The previous broader criterion that relied on a general designation of "complex medical status" has been removed. Instead, the policy now requires documentation of specific conditions (for example, medical instability with risk of requiring hospital‑only equipment, inability to tolerate fluid load, or severe vascular access issues) to justify hospital outpatient administration.

Coding and Billing References

Covered CPT Codes (reference)CPT

90283	Immune globulin (IGIV), human, for intravenous use.
90284	Immune globulin (SCIG), human; for use in subcutaneous infusions, 100 each mg.

Covered HCPCS/J/Q Codes (reference)HCPCS

J0129	Injection, abatacept; 10 mg
J1426	Injection, casimersen, 10 mg
J1427	Injection; viltolarsen, 10 mg
J1428	Injection; eteplirsen, 10 mg
J1429	Injection, golodirsen, 10 mg
J1459	Injection, immune globulin (Privigen); intravenous, nonlyophilized liquid, 500 mg
J1551	Injection, immune globulin (Cutaquig), 100 mg
J1552	J1552
J1554	Injection, immune globulin (Asceniv), 500 mg
J1555	Injection, immune globulin (Cuvitru), 100 mg

1–10 of 25

1/3

Place of Service codes citedModifier

22	On Campus-Outpatient Hospital (Place of Service)
19	Off Campus-Outpatient Hospital (Place of Service)

Applicable HCPCS CodesHCPCS

J1552	HCPCS code revised (listed in revision notes)
J1628	HCPCS code revised (listed in revision notes)
Q5133	HCPCS code description revised
Q5135	HCPCS code added/revised

Ongoing hospital outpatient facility authorization duration

Maximum authorization durationOngoing hospital outpatient facility-based infusion authorization will be no more than 6 months to allow reassessment for alternative site of care.

Greatest applicable periodIf more than one criterion applies, the greatest of the applicable approval time periods will be allowed.

ContextApplies to specialty medications that require health‑care provider administration listed in the policy.

Re-initiation interval exclusion

Re‑initiation exclusionExcludes drugs dosed at an interval of 6 months or greater from the re‑initiation requirement for outpatient hospital facility‑based administration.

Prior Authorization, Documentation, and Provider Requirements

Prior Authorization

Prior Authorization Required

Prior authorization is required for outpatient hospital facility infusion services. Submission of medical records documenting that outpatient hospital facility-based administration is medically necessary is required when at least one of the listed clinical criteria is met. Failure to submit required documentation when at least one criterion exists may result in denial of the request.

Applies to hospital outpatient facility infusion services (Place of Service 19, 22 and other applicable outpatient hospital codes).
When prior authorization is requested, include supporting medical records that demonstrate meeting one or more of the medical necessity criteria in the Coverage Rationale.

Billing Rule

Prior Authorization — Codes and Billing

Prior authorization requests must include the applicable procedure and HCPCS codes for the drug and administration. Listing a code in this policy does not guarantee coverage; benefit determination is subject to federal, state, and contractual rules.

Definitions and Key Terms

Site of Care definition

DefinitionSite of Care = physical location for infusion administration, including hospital inpatient, hospital outpatient, physician office, ambulatory infusion suite, or home-based setting.

Hospital inpatient/outpatientIncludes on‑campus and off‑campus hospital settings for higher‑acuity administrations.

Non‑hospital settingsOther acceptable sites include physician office, ambulatory infusion suites, and home infusion arrangements when clinically appropriate.

Immune Globulin definition

DefinitionImmune Globulin refers to Immunoglobulin G (IgG) products used for replacement therapy; references to Immune Globulin in this policy refer to IgG administered IV (IVIG/IGIV) or subcutaneously (SCIG/IGSC).

Synonyms

Initial Therapy — Specific Requirements

Initial IGIV administration

All initial infusions of IGIV should be administered under physician supervision in a facility prepared to manage severe acute medical complications:

Initial IGIV requirement: All initial infusions of IGIV should be administered under physician supervision in a facility prepared to manage the most severe acute medical complications.

Changes in IGIV products also require physician supervision in similar facilities

Initial therapy

Initial therapy — considerations for initial infusion or re‑initiation:

Initial infusion may be considered for outpatient hospital facility-based administration, particularly when there is concern for elevated risk at alternative sites; initial infusion language excludes drugs dosed at intervals ≥6 months from re-initiation criteria.

Continuation and Re-initiation Criteria

Continuation therapy limits

Ongoing hospital outpatient facility-based infusion limits and reassessment:

Ongoing therapy: Ongoing outpatient hospital facility-based infusion is limited to no more than 6 months to allow reassessment for alternative site of care.<= 6 months

If more than one applicable approval time period exists, the greatest is allowed

Re-initiation/Continuation

Re‑initiation/Continuation rules for renewal of therapy after lapse:

Re-initiation after >6 months: Re-initiation of previous therapy after more than 6 months (excludes drugs dosed at an interval of 6 months or greater) may require outpatient hospital facility-based administration for a short duration (e.g., 4 weeks).

Step Therapy and Initial Infusion Site Requirements

Requirement	Details
Initial IGIV and product changes site-of-care requirement	All initial infusions of IGIV and changes in IGIV products must be provided under physician supervision in a facility prepared to manage the most severe acute medical complications.

Situation	Coverage action / typical duration
Initial infusion or re-initiation after >6 months (for drugs dosed more frequently than every 6 months)	May require outpatient hospital facility–based administration for a short duration (example: ~4 weeks). Excludes drugs dosed at intervals of 6 months or greater.

Site-of-Care Guidance

Note

Hospital outpatient administration allowed when criteria documented

Hospital outpatient facility administration is allowed when medical records document that at least one specified medical‑necessity criterion is met; otherwise alternative sites of care should be used.

Note

Home infusion accepted — may have lower infection risk and high satisfaction

Home infusion and other non‑hospital outpatient settings are accepted and preferred when criteria for hospital outpatient infusion are not met; home infusion may have lower infection rates and high patient satisfaction in selected patients.

Prior Authorization

Authorization requires documentation of ≥1 specified criterion

Authorization for outpatient hospital, home, or office administration requires documentation that at least one specified medical‑necessity criterion is met (e.g., medical instability, prior severe adverse events unresponsive to interventions, unsuitable home environment, initial/re‑initiation exceptions); when multiple criteria apply, the greatest approval period is allowed.

Background and Clinical Context

Immunoglobulin G (IgG) replacement therapy (IVIG/IGIV or SCIG/IGSC) is used to replace deficient IgG in patients with immunodeficiency. IVIG is typically administered intravenously on a monthly schedule, while SCIG is often given weekly or every two weeks. Both routes effectively restore protective IgG levels, and patients and clinicians should weigh the risks and benefits of each Site of Care (hospital outpatient, ambulatory infusion suite, office, or home) when planning therapy. Hospital‑level administration is reserved for situations where the documented clinical criteria indicate increased risk that cannot be managed safely in alternative settings.

Biosimilars and Reference Biologics

Billing Rule

Remicade (infliximab) — biosimilars and HCPCS Q‑codes listed

Remicade (infliximab) and its biosimilars are listed alongside reference biologics; the policy provides HCPCS Q‑codes for biosimilars (e.g., Q5103, Q5104, Q5121) and lists updated HCPCS codes in the revision notes.

Revision History and Material Changes

2025-05-01material revisionLatest

Replaced prior wording to require submission of medical records documenting that outpatient hospital facility-based administration is medically necessary; added notation on selecting the greatest applicable approval period when multiple criteria apply; added a criterion for medical instability with examples (e.g., need for endotracheal tube, chest tube equipment, cricothyroidotomy set, mechanical ventilator; cardiopulmonary conditions; inability to tolerate fluid volume load; severe vascular access issues).

2025-05-01material revision

Clarified prior severe adverse event requirement to specify events must have occurred while receiving the requested therapy (excluding first or second infusion) and been unresponsive to standard interventions before considering higher-risk alternate sites of care.